Thrilled to speak at the #KUICE_T symposium on the role of #CAR_T in solid tumors! Huge thanks to Al-Ola A Abdallah MD (USMIRC) & Nausheen Ahmed MD for the invitation. The event was incredibly insightful, showcasing the latest in cellular therapeutics for hematology and oncology! KU Cancer Center

Lead authors Barry Paul Shebli Atrash Nausheen Ahmed MD Muhammad Umair Mushtaq (Abu Mikael) Faiz Anwer MD mdpi.com/2072-6694/16/1… #mmsm #myeloma #MedTwitter #MedEd #USMIRC

Is CAR T-cell therapy a miracle or a gamble? Discover the groundbreaking treatment's potential and risks, and learn how evolving guidelines could improve patient outcomes in this exclusive interview! Nausheen Ahmed MD KU Cancer Center one.targetedonc.com/launch/six.eig…

Hot off Press: Safety and Efficacy of #CART in #RRMM w sec #AL #Amyloidosis led by resident Cleveland Clinic ➡️Responses were rapid and deep ➡️No excessive or ⬆️Gr CRS ➡️Presence of amyloid should not be🛑🚧 CART pubmed.ncbi.nlm.nih.gov/39189919/ #mmsm #MedTwitter #UnmetNeed eJHaem Journal

1/ Now in Blood Cancer Journal - our work to chronicle disparities specifically in R/R myeloma and why they matter 🧵 1️⃣ Trial-studied vs optimal drug dosing 2️⃣ Racial & socioeconomic gaps re: CAR-T & bsAbs 3️⃣ #MMsm supportive care, inc PCP access, and more nature.com/articles/s4140…

Balancing access and safety in CAR T-cell therapy 🌟 Discover how monitoring practices and REMS updates are evolving and what it means for institutions in this exclusive interview with William Wesson of KU Cancer Center. #CAR-T one.targetedonc.com/launch/six.eig…

I find it odd to hear oncologists call themselves or colleagues Giants Rising stars Rock stars Most of the decline in cancer deaths is just due to smoking cessation. Many 'Giants' developed a drug with a 1 month PFS gain.

Nausheen Ahmed MD of KU Cancer Center discusses issues with access to CAR T-cell therapy that a recent study explored. targetedonc.com/view/improving…

#SOHO2024 poster sessions. Reaching the stars! KU Cancer Center #USMIRC Fathima shehnaz Al-Ola A Abdallah MD (USMIRC) Al-Ola A Abdallah MD (USMIRC) KU Heme Onc Fellowship

Nahid Suleman presenting his work on #CART and #ICANS #Soho2024

Here for a day full of learning and meeting leaders of the field. #SOHO2024 happy with how our posters turned out! Hira Shaikh It was so lovely finally meeting you in person Nausheen Ahmed MD USMIRC News

With Nausheen Ahmed MD at SOHO 2024. Creating waves in oncology . #SOHO2024

Passionately curious about hematology #SOHO2024

#SOHO2024

Only a matter of time! Now in NEJM: Rapid remission in refractory lupus with teclistamab (BCMA bsAb) x5 wks, including 3rd SUD. Authors astutely note that CD19 CARs also work here... sounds like the #lymsm and #MMsm fields will compete for which of our fields cures lupus 1st!

Day 2 of SOHO !! Young investigator scholarship

Study: Are we over-monitoring CAR T-cell therapy patients? New research led by Dr. Nausheen Ahmed shows that new-onset CRS & ICANS are “exceedingly rare” after 2 weeks in #NonHodgkinlymphoma cases. bit.ly/3SyfA6X Nausheen Ahmed MD KU Cancer Center Kai Rejeski

Our analysis of CAR-T in #PCNSL, CIBMTR N=24; median age 57; 88% active disease; median piror Rx4; ORR 61%; 2yr OS/PFS 50%/28%; NRM 0; CRS 67%; no G3-4. ICANS 33%; 2 with grade or higher. #lymsm #CART Catherine Lee Mazyar Shadman, MD MPH Hemant S. Murthy MD et al. haematologica.org/haematologica/…